Occupational Therapists in Coldwater, OH Accepting Medicare
7 Occupational Therapists found. Showing 1 - 7
 Julia Eyink Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 100 Don Desch Dr, Coldwater, OH 45828 Phone: 419-584-9148 |
Taylor Spaulding, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 100 Don Desch Dr, Coldwater, OH 45828 Phone: 419-584-9148 |
Michelle Imwalle Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 800 W Main St, Coldwater, OH 45828 Phone: 419-678-5125 |
Lindsey Tuente Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 100 Don Desch Dr, Coldwater, OH 45828 Phone: 419-584-9148 |
Kayla Dorsten, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 800 W Main St, Coldwater, OH 45828 Phone: 419-678-5125 |
Kathryn Burke, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 800 W Main St, Coldwater, OH 45828 Phone: 419-678-5125 |
Taylor Marie Bendele, MOT, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 800 W Main St, Coldwater, OH 45828 Phone: 419-678-5125 |
News Archive
Mayo Clinic biostatistician become director of CALGB
In a move that will improve efficiency and collaboration in cancer research, Mayo biostatistician Daniel Sargent, Ph.D., will become director of the Statistical Center for the Cancer and Leukemia Group B (CALGB), a national association of cancer researchers funded primarily by the National Cancer Institute (NCI).
Titan Medical, CAE Healthcare partner to develop the world's next generation robotic surgery platform
Titan Medical Inc. announced today that it has signed an agreement with CAE Healthcare for various services related to the development of Titan's Amadeus® clinical-grade robotic surgery platform. Once completed, the platform could be used, not only to perform surgery at a distance, but also to train surgeons via simulation.
Regeneron, Sanofi initiate enrollment in SAR236553/REGN727 Phase 3 program
Sanofi and Regeneron Pharmaceuticals, Inc. announced today that several trials within ODYSSEY, the Phase 3 clinical program of SAR236553/REGN727, have initiated patient enrollment.
Gilead to acquire Arresto
Gilead Sciences, Inc. and Arresto Biosciences, Inc., a privately-held, development-stage biotechnology company focused on medicines to treat fibrotic diseases and cancer, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Arresto. Under the terms of the agreement, Gilead will acquire Arresto for $225 million and potential future payments based on achievement of certain sales levels.
Mass spectrometry could aid biodefense in rapidly detecting dangerous pathogens
Scientists have used mass spectrometry for decades to determine the chemical composition of samples but rarely has it been used to identify viruses, and never in complex environmental samples.
› Verified 1 days ago
Physical Therapists
Occupational Therapists
Optometrists
Speech-Language Pathologists
Chiropractors
Podiatrists